GETI.B

209.6

+1.26%↑

CAMX

610

+1.92%↑

BIOAB

318.8

+0.82%↑

EKTA.B

55.8

+0.45%↑

VITR

138.6

+1.02%↑

GETI.B

209.6

+1.26%↑

CAMX

610

+1.92%↑

BIOAB

318.8

+0.82%↑

EKTA.B

55.8

+0.45%↑

VITR

138.6

+1.02%↑

GETI.B

209.6

+1.26%↑

CAMX

610

+1.92%↑

BIOAB

318.8

+0.82%↑

EKTA.B

55.8

+0.45%↑

VITR

138.6

+1.02%↑

GETI.B

209.6

+1.26%↑

CAMX

610

+1.92%↑

BIOAB

318.8

+0.82%↑

EKTA.B

55.8

+0.45%↑

VITR

138.6

+1.02%↑

GETI.B

209.6

+1.26%↑

CAMX

610

+1.92%↑

BIOAB

318.8

+0.82%↑

EKTA.B

55.8

+0.45%↑

VITR

138.6

+1.02%↑

Inicio・Lista de Acciones・Vivesto AB

Vivesto AB

Abierto

0.22

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.22

Máximo

0.22

Métricas clave
By Trading Economics
Ingresos	2.3M -7.2M
BPA	-0.013
Empleados	4

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-8.3M 70M
Apertura anterior	0.22
Cierre anterior	0.22

Vivesto AB Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 dic 2025, 23:58 UTC

Adquisiciones, fusiones, absorciones

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 dic 2025, 23:56 UTC

Ganancias

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 dic 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 dic 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dic 2025, 21:50 UTC

Ganancias

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 dic 2025, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

11 dic 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 dic 2025, 23:37 UTC

Charlas de Mercado

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 dic 2025, 23:31 UTC

Ganancias

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dic 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 dic 2025, 22:35 UTC

Ganancias

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 dic 2025, 22:30 UTC

Ganancias

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 dic 2025, 22:09 UTC

Adquisiciones, fusiones, absorciones

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 dic 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 dic 2025, 22:05 UTC

Ganancias

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dic 2025, 21:51 UTC

Adquisiciones, fusiones, absorciones

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

11 dic 2025, 21:39 UTC

Ganancias

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 dic 2025, 21:39 UTC

Ganancias

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 dic 2025, 21:38 UTC

Ganancias

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 dic 2025, 21:37 UTC

Ganancias

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 dic 2025, 21:37 UTC

Charlas de Mercado

Broadcom Sees AI Revenue Doubling -- Market Talk

11 dic 2025, 21:34 UTC

Adquisiciones, fusiones, absorciones

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 dic 2025, 21:29 UTC

Adquisiciones, fusiones, absorciones

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 dic 2025, 21:28 UTC

Charlas de Mercado

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Dexus: Third Party Investors to Contribute Remainder

11 dic 2025, 21:27 UTC

Adquisiciones, fusiones, absorciones

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 dic 2025, 21:26 UTC

Adquisiciones, fusiones, absorciones

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 dic 2025, 21:25 UTC

Adquisiciones, fusiones, absorciones

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Comparación entre iguales

Cambio de precio

Vivesto AB previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.